Sophia Genetics: Differentiating Through Decentralization and Data Federation in Precision Medicine

I. Executive Summary

This report analyzes Sophia Genetics’ unique market position, its core technologies, and its strategic differentiators in the competitive field of data-driven medicine.

Sophia Genetics SA (NASDAQ: SOPH) has established a standout position in the field of genetics and precision medicine. Its differentiation stems from the strategic integration of three foundational pillars:

A technologically advanced, multimodal, and decentralized Software-as-a-Service (SaaS) platform known as SOPHiA DDM™.
A disruptive business model that fosters a powerful, compounding network effect by empowering global healthcare institutions with data sovereignty.
A deep, biology-first intellectual property core of proprietary artificial intelligence (AI) algorithms.

The company’s core technological differentiator is the SOPHiA DDM™ platform. This cloud-native system is engineered to ingest, harmonize, and analyze complex multimodal data sets. Its capabilities extend beyond standard genomics. The platform incorporates radiomics (extracting quantitative data from medical images), digital pathology (analyzing digitized pathology slides), and other clinical data. This provides a holistic analytical framework for understanding complex diseases like cancer and rare disorders.¹⁻³ This approach marks a significant departure from genomics-centric competitors and positions the company at the forefront of integrated diagnostics.

Strategically, Sophia Genetics distinguishes itself through a decentralized business model. This model fundamentally alters the customer relationship. Instead of requiring institutions to send sensitive patient samples to a central laboratory, the company provides analytical software for institutions to perform complex genomic testing in-house.⁴,⁵ This approach addresses the critical institutional need for data control, privacy, and security. It transforms Sophia Genetics from a service vendor into an embedded technology partner.

This decentralized model powers the company’s most formidable competitive advantage: a global network of over 800 healthcare institutions.⁴ This network creates a powerful virtuous cycle, or network effect. As more institutions use the platform, the collective, anonymized data refines the platform’s AI algorithms, enhancing their accuracy. This, in turn, attracts more users. The result is a “collective intelligence” that serves as a significant and growing competitive moat.²,⁴,⁶

Financially, Sophia Genetics exhibits the characteristics of a high-growth SaaS company. It shows consistent revenue growth and improving adjusted gross margins reaching over 70%. The company has also articulated a clear strategy to achieve adjusted EBITDA breakeven by the end of 2026.⁷⁻⁹ This financial profile, combined with its unique strategic positioning, supports a forward-looking outlook. Sophia Genetics is poised to become a fundamental operating system for institutional precision medicine programs worldwide.

II. Corporate and Strategic Foundation: The Mission to Democratize Data-Driven Medicine

A Visionary Founding and Mission-Driven Strategy

Sophia Genetics was founded in 2011 as a spin-out from the prestigious École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. Its multidisciplinary founding team of biologists and data scientists included Dr. Jurgi Camblong, Professor Lars Steinmetz, and Dr. Pierre Hutter.²,¹⁰ The company’s origins within a leading academic environment are the bedrock of its entire corporate strategy.

The company’s stated mission is to “Democratize Data-Driven Medicine, Together”.⁴,¹¹ This principle drives its strategic decisions. The objective is to create a future where every patient has equal access to world-class, data-driven precision care, regardless of their location.⁴,¹² This mission directly addresses a significant impediment to advancing precision medicine: the pervasive siloing of critical health data within and between institutions.²,¹¹

The founders’ academic background provided a crucial perspective on data sharing challenges. They recognized that large medical institutions would be reluctant to relinquish control over their valuable patient data. This understanding led to the deliberate choice of a decentralized platform architecture. Unlike a centralized model, the SOPHiA DDM™ platform brings analytical power directly to the institution. This allows them to maintain full sovereignty over their data, a key factor in unlocking global collaboration.⁴,⁵

Leadership and Scientific Acumen

The deep expertise of its leadership team reinforces the company’s credibility. A significant portion of employees hold advanced degrees. 30% of the total workforce and over 80% of its scientific personnel possess PhDs in fields ranging from molecular biology to computer science.⁴,¹³

Founder and CEO Dr. Jurgi Camblong is a molecular biologist with publications in premier scientific journals such as Cell, Science, and Nature, lending the company profound scientific credibility.¹⁴ The executive team combines this scientific depth with extensive industry experience. Chief Scientific Officer Dr. Zhenyu Xu is a genome scientist who led the DDM platform’s development and is a leading expert in clinical next-generation sequencing (NGS) data analysis.¹³ This fusion of deep biological understanding with market-aware product strategy ensures that technological development solves real-world clinical problems.

Key Corporate Milestones

The company’s history is marked by a series of strategic milestones illustrating its growth:

2014: Launched the SOPHiA DDM™ platform, one of the world’s first cloud-based healthcare analytics platforms for routine diagnostic use.¹⁰
2018: Expanded its global footprint by establishing a U.S. headquarters in Boston and acquiring French analytics software company Interactive Biosoftware.¹⁰
2021: Completed its Initial Public Offering (IPO) on the Nasdaq exchange under the ticker SOPH, securing capital for expansion.¹⁰,¹⁵
2025: Surpassed the milestone of analyzing two million patient genomic profiles, highlighting widespread adoption and the immense dataset informing its AI.⁴,⁶

III. The SOPHiA DDM™ Platform: An AI-Powered, Multimodal Engine for Global Insights

Core Architecture: A Cloud-Native, SaaS, and Technology-Agnostic Platform

The SOPHiA DDM™ (Data-Driven Medicine) platform is the company’s technological heart. It is a cloud-native, Software-as-a-Service (SaaS) platform providing a secure, scalable, and globally accessible environment for advanced data analysis.¹⁵⁻¹⁷ Its SaaS design allows for continuous updates and rapid feature deployment across its user network.

A critical design feature is that the platform is “technology-agnostic”.³,⁵ It seamlessly integrates with a wide variety of existing laboratory systems, workflows, and sequencing instruments. This interoperability removes a significant barrier to entry for laboratories, allowing them to augment their capabilities without a complete infrastructure overhaul.

The company built the platform with security and regulatory compliance as a core tenet. It complies with major international data protection regulations, including HIPAA and GDPR, and holds key ISO certifications for cloud security and data privacy.⁴,⁵,¹⁸ This robust security framework is essential for earning institutional trust.

Multimodal Capabilities: Beyond Genomics

While founded in genomics, the platform’s primary differentiator is its advanced capability to analyze and integrate multimodal data. This strategy acknowledges that a comprehensive understanding of disease requires insights from multiple sources.

The platform is structured into interconnected modules:

SOPHiA DDM™ for Genomics: The core module for analyzing NGS data to identify and classify genomic variants in oncology and rare disorders.⁵,¹⁹
SOPHiA DDM™ for Radiomics: Unlocks insights from medical imaging data (CT, MRI, PET scans) using AI for tasks like automated image segmentation and feature extraction.³,¹⁸,²⁰
SOPHiA DDM™ for Multimodal: Integrates data from genomics, radiomics, clinical records, and digital pathology to build predictive models for a more complete view of a patient’s disease.¹,²

This multimodal approach represents a strategic bet on the future of precision medicine. While many competitors focus on genomics alone, Sophia Genetics is building the infrastructure to synthesize the full spectrum of patient data. This positions the company to uncover biological patterns impossible to derive from a single data type. A collaboration with GE HealthCare to integrate imaging and genomic data is a tangible example of this strategy in action.¹⁰,¹⁹

The “New Generation” Platform: A Leap in Computational Power

In September 2024, Sophia Genetics launched the “New Generation” of the SOPHiA DDM™ platform.³,²² This new iteration features a modernized, web-based architecture built on a microservices framework. This structure improves efficiency and scalability. For users, it means the company can develop and deploy new features more rapidly, ensuring the platform evolves to meet new clinical needs.²²

Strategic collaborations with computing leaders power this technological leap. The platform leverages Microsoft Azure for its cloud infrastructure and integrates NVIDIA’s Parabricks software for GPU-accelerated computing.³,¹⁰,¹⁹,²³ This partnership provides the massive computational power required to process increasingly complex datasets. This makes computationally intensive applications like Whole Genome Sequencing (WGS) and multimodal analyses feasible at scale for the company’s global user base.¹⁹,²²

IV. The Intellectual Property Core: Proprietary Algorithms and Patent Strategy

A Suite of AI-Powered Analytical Engines

The SOPHiA DDM™ platform’s analytical power resides in its core intellectual property: a suite of proprietary and patented algorithms. These AI-driven engines solve specific, difficult challenges in analyzing complex biological data. They are the result of over a decade of R&D, refined by data from over two million patient profiles.⁶,¹⁸

Key algorithms include:

GIInger™: A deep learning algorithm that assesses genomic instability. This is clinically significant because it helps determine a tumor’s Homologous Recombination Deficiency (HRD) status, a critical biomarker used to guide therapy decisions in cancers like ovarian and breast cancer.¹⁸,²⁴
MUSKAT™: A sophisticated algorithm that solves the difficult problem of detecting copy number variations (CNVs). Its unique normalization technique allows it to accurately identify these events even in low-quality samples where other tools might fail.¹⁸,²⁵
CUMIN™: A proprietary technology that uses molecular barcodes to filter out errors from the sequencing process. This is essential for demanding applications like liquid biopsy, as it enables the highly sensitive detection of cancer-related variants at very low frequencies.⁵,²⁶
PEPPER™: An algorithm that uses pattern recognition to accurately identify single nucleotide variants (SNVs) and small insertions/deletions (Indels). It solves the core challenge of distinguishing true biological signals from the technical “noise” in sequencing data.¹⁸,²⁴,²⁵
MOKA™: A robust variant annotation algorithm that provides crucial context to identified genetic variants. It assesses the likely functional impact of a variant, helping clinicians understand its clinical significance.²⁴,²⁵
STAR ANISE: An algorithm specialized for pharmacogenomics that accurately identifies variations in drug-metabolizing genes. This helps predict how a patient might respond to certain medications.¹⁸,²⁵

The table below summarizes these key technological assets.

Algorithm Name	Core Technology Principle	Primary Function	Key Clinical Application(s)
GIInger™	Deep Learning (Convolutional Neural Network) analyzing low-pass whole genome sequencing data to assess genomic instability.	Genomic Instability Scoring	HRD Status Assessment (Ovarian, Breast, Prostate Cancer)
MUSKAT™	Statistical Inference with double normalization to accurately detect Copy Number Variations (CNVs), even in low-quality samples.	Copy Number Variation (CNV) Detection	Gene Amplification/Deletion Analysis (Oncology)
CUMIN™	Molecular Barcoding (Unique Molecular Identifiers) used to filter out sequencing errors and enable highly sensitive variant detection.	Error Correction & Low-Frequency Variant Detection	Liquid Biopsy, Minimal Residual Disease (MRD) Monitoring
PEPPER™	Pattern Recognition to distinguish true biological signals from technical noise in sequencing data.	SNV & Indel Calling	General Variant Detection (Oncology, Rare Disease)
MOKA™	Database Curation & De Novo Analytics to contextualize variants using curated databases and predictive methods.	Variant Annotation & Pathogenicity Prediction	Variant Interpretation (All Genomic Applications)
STAR ANISE	Statistical Inference leveraging the PharmVar database to accurately call star alleles for pharmacogenomic applications.	Star Allele Calling	Pharmacogenomics (PGx)
CARDAMOM™	Statistical Inference for detecting gene fusions and exon skipping events.	Gene Fusion & Exon Skipping Detection	Oncology Biomarker Identification
MUSTARD™	Statistical Inference using a curve-fitting algorithm to identify differences in read length distribution for MSI detection.	Microsatellite Instability (MSI) Detection	MSI Status Assessment (Colorectal, Endometrial Cancer)

Patent Portfolio and Strategic Litigation

Sophia Genetics protects its innovations through a robust patent strategy. As of mid-2025, the company held 56 granted patent families with 43 additional applications pending.²⁷ This portfolio covers fundamental methods in genomic analysis, such as techniques for allele-specific copy number detection.²⁷,²⁸

The technology’s strategic value is underscored by its involvement in high-stakes patent litigation. Guardant Health, a dominant player in the liquid biopsy market, is suing Sophia Genetics in both the UK High Court and the Unified Patent Court (UPC) in Paris.²⁹ Guardant alleges that Sophia Genetics’ “MSK-ACCESS® powered with SOPHiA DDM™” offering infringes on four of its European patents covering liquid biopsy methods and the use of genomic databases.²⁹

While this litigation presents a business risk, it also serves as powerful market validation. Guardant’s decision to pursue costly, multi-jurisdictional legal action suggests the market leader views Sophia Genetics’ decentralized model as a significant competitive threat. The dispute represents a fundamental conflict between two opposing business models for the future of diagnostics. Sophia Genetics’ model empowers any hospital to deploy a world-class liquid biopsy test in-house, directly challenging the revenue of centralized service providers like Guardant.

V. A Disruptive Business Model: Decentralization, SaaS, and the Network Effect

The Decentralized Model: Empowering the Customer

Sophia Genetics’ most profound strategic choice is its commitment to a decentralized business model. This stands in stark contrast to competitors who operate on a centralized laboratory service model, where hospitals ship patient samples to the company’s lab for analysis.

Sophia Genetics reverses this paradigm. It provides customers with the software platform needed to perform complex data analysis within their own laboratories.⁴,⁵,¹¹

This decentralized approach offers a compelling value proposition. It allows institutions to maintain complete control and sovereignty over their sensitive patient data.⁴,⁵ In an era of increasing focus on data privacy and security, this is a decisive advantage. It transforms the relationship from a client-vendor transaction to an integrated technology partnership.

Consumption-Based SaaS Revenue Streams

The company’s business model is built on recurring, consumption-based Software-as-a-Service (SaaS) revenue.¹⁵,¹⁷ Customers subscribe to the SOPHiA DDM™ platform and pay based on usage. The price per analysis typically ranges from $100 to $500, depending on the application’s sophistication.²

This SaaS model provides a predictable and scalable revenue stream. Because the primary product is software, the model also yields high gross margins. The company reported an adjusted gross margin of 72.8% for 2024, a figure more characteristic of an enterprise software company than a traditional lab services business.⁷,⁹

The Network Effect: Creating “Collective Intelligence”

The decentralized model is the engine for the company’s most powerful competitive advantage: the network effect. By connecting over 800 healthcare institutions across more than 70 countries, the platform has created one of the largest federated data networks in precision medicine.²,⁴,¹⁶

This network effect creates a self-reinforcing, virtuous cycle. While each institution’s raw patient data remains secure, the anonymized insights and algorithm performance data are fed back into the system to continuously improve the core AI models.²,⁴,¹⁹

The process works as follows:

An institution joins the network and begins analyzing its patient data.
The platform’s AI algorithms benefit from this new, diverse data, improving their accuracy.
The improved algorithms provide greater value to all existing members of the network.
This increased value attracts new institutions to join the platform.
The cycle repeats, with each new member making the entire network more intelligent.

This “collective intelligence” is a powerful, compounding asset.⁴,¹⁵ A competitor cannot replicate this value simply by developing a comparable algorithm. They would need to replicate the entire global network of contributing institutions, a feat that has taken Sophia Genetics over a decade to build. This ecosystem-level advantage is a structural barrier to entry that grows stronger with every new customer. The company has formalized this approach through initiatives like SOPHiA UNITY, a research network for multimodal oncology studies.³⁰

VI. Financial Analysis and Path to Profitability

Revenue Growth and Composition

Sophia Genetics has demonstrated a consistent track record of top-line growth. The company’s revenue increased from $62.4 million in 2023 to $65.2 million in 2024.⁹,³¹,³² Management projects revenue for 2025 in the range of $72 million to $76 million, representing 10% to 17% year-over-year growth.⁷,³³

Over 90% of this revenue is derived from the recurring, consumption-based use of the SOPHiA DDM™ platform.²,⁹ A primary key performance indicator (KPI) is analysis volume, which grew by 11% in 2024 to a record 352,000 analyses.³⁴

Profitability and Margin Analysis

Like many high-growth companies, Sophia Genetics is not yet profitable on a net income basis. The company reported a net loss of $62.5 million for 2024.⁹,³² However, this was a significant improvement from the $79.0 million net loss in 2023, indicating progress toward financial sustainability.³²,³⁵

A more telling metric is its high and expanding adjusted gross margin. This figure reached an impressive 72.8% in 2024 and climbed to 75.7% in the first quarter of 2025.⁷⁻⁹ This strong margin performance reflects the scalability of a software-centric business model. As revenue grows, the costs of data processing do not increase at the same rate. The company’s adjusted operating loss also improved by 20% year-over-year in 2024.⁷,²³

This financial profile is more analogous to a high-growth enterprise SaaS company than a traditional diagnostics firm. The consistent improvement in gross margin is a powerful signal that the business model is fundamentally scalable and sound.

Stated Path to Profitability

Management has provided a clear timeline for achieving profitability. Sophia Genetics expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA during the second half of 2027.⁷⁻⁹ To support this goal, the company ended the second quarter of 2025 with $94.8 million in cash and cash equivalents.³³

The table below summarizes key financial trends.

Metric	FY 2023	FY 2024	YoY Change (%)
Total Revenue	$62.4 million	$65.2 million	+4.5%
Platform Revenue	$60.9 million	$63.5 million	+4.3%
Gross Profit (Adjusted)	$45.1 million	$47.5 million	+5.3%
Gross Margin (Adjusted)	72.2%	72.8%	+60 bps
Operating Loss (Adjusted)	$(56.0) million$	$(44.8) million$	-20.0%
Net Loss	$(79.0) million$	$(62.5) million$	-20.9%
Total Analyses Performed	~317,000	352,000	+11.0%

*Note: Financial data is sourced from company financial reports.*⁷,⁹,³²,³⁴,³⁵

VII. Competitive Landscape: A Differentiated Player in a Crowded Field

Categorizing the Competition

The precision medicine landscape is populated by a diverse array of companies. Competition for Sophia Genetics can be segmented into two primary categories.

Centralized Laboratory Service Providers: This is the dominant model in the U.S. market. These companies operate large, central labs that receive patient samples for analysis. Key players include Guardant Health³⁶,³⁷, Caris Life Sciences³⁸,³⁹, and NeoGenomics Laboratories⁴⁰,⁴¹.
Other Platform & Software Providers: These companies, like Sophia Genetics, provide software and data analytics solutions to healthcare institutions. This group includes Tempus AI⁴²,⁴³ and PierianDx (now part of Velsera).⁴⁴,⁴⁵

Core Differentiators

Sophia Genetics has carved out a unique position by deliberately choosing a strategy that differs from both competitive archetypes.

Against centralized labs, the differentiation is fundamental:

Business Model: Sophia Genetics offers a decentralized SaaS platform, while competitors offer an outsourced testing service.
Data Strategy: Sophia Genetics enables a federated network where institutions retain control of their data. Centralized labs aggregate all data under their own control.
Value Proposition: Sophia Genetics empowers customers to build their own in-house precision medicine programs. Competitors provide a discrete, transactional service.

Against other platform providers, the differentiation is more nuanced:

Multimodality: The deep integration of genomics, radiomics, and other clinical data is more central to the SOPHiA DDM™ platform’s long-term strategy.¹,²⁰
Global Network Scale: The size and diversity of the Sophia Genetics network provide a data advantage for training AI models on real-world patient populations.⁴,⁶
Biology-First Focus: The company’s deep expertise in molecular biology ensures its platform is purpose-built to solve complex biological problems, not just IT challenges. This translates into more accurate algorithms and a product roadmap aligned with real-world clinical needs.⁴,¹¹

The following table contrasts the strategic positioning of Sophia Genetics against its key competitors.

Company	Primary Business Model	Data Strategy	Key Value Proposition
Sophia Genetics	Decentralized SaaS Platform	Federated Network (Customer Data Sovereignty)	Empowering institutions with in-house, multimodal analytical capabilities and access to collective intelligence.
Guardant Health	Centralized Lab Services	Centralized Data Aggregation	Providing best-in-class liquid biopsy testing as an outsourced service.
Caris Life Sciences	Centralized Lab Services	Centralized Data Aggregation	Comprehensive, multi-omic tumor profiling to guide therapy decisions.
Tempus AI	Hybrid (Centralized Lab Services + Data Platform)	Centralized Data Aggregation	Leveraging a massive, centralized dataset and AI to provide both testing services and data insights for research.

This comparison highlights that Sophia Genetics competes on a strategic level. It offers a fundamentally different way for healthcare to adopt and scale precision medicine. For example, a hospital can either send a blood sample to Guardant Health for a liquid biopsy test or license an application on the SOPHiA DDM™ platform to run that same type of test in-house.²³ By choosing the latter, the hospital builds internal expertise, retains control over the data, and integrates the process into its workflows. Sophia Genetics sells institutional empowerment, a disruptive proposition for sophisticated healthcare systems.

VIII. Synthesis and Strategic Outlook

A Synthesized Argument for Uniqueness

Sophia Genetics stands out because it has architected its business around a distinct vision for precision medicine. This vision is decentralized, collaborative, and multimodal.

The company’s uniqueness is not found in a single algorithm or feature. Instead, it lies in the powerful symbiosis between its core components.

The mission to democratize data-driven medicine directly informed the choice of a decentralized technology platform. This platform enabled a SaaS business model that respects customer data sovereignty. Respecting data sovereignty was the key to building a vast global network.

This network now generates the collective intelligence that makes its AI-powered technology a leader in the field. This tightly integrated, self-reinforcing loop of mission, technology, business model, and network effect creates a unique and defensible market position.

Key Opportunities (Future Growth Vectors)

Looking forward, Sophia Genetics is well-positioned to capitalize on several growth opportunities:

BioPharma Services Expansion: The company’s global network is an exceptionally valuable asset for pharmaceutical companies. For instance, a partner could leverage the network to rapidly identify a global cohort of patients with a rare mutation for a clinical trial, drastically reducing recruitment time.⁴⁶,⁴⁷ Collaborations with industry giants like AstraZeneca and Myriad Genetics indicate the potential in this segment.¹,²³
Leveraging the Multimodal Dataset: As the integrated data on the platform grows, the company is uniquely positioned to develop novel, AI-driven biomarkers. For example, the platform could develop an algorithm that combines genomic data with radiomic features from a CT scan to better predict a patient’s response to a specific immunotherapy.
Geographic Expansion: The company has significant runway for growth in key markets. In 2024, analysis volumes in North America and the Asia-Pacific (APAC) region grew by 33% and 40% year-over-year, respectively, demonstrating strong momentum.³⁴

Identified Risks and Challenges

Despite its strong strategic position, the company faces several risks:

Intense Competition: The centralized lab model may present a simpler solution for smaller institutions. Sophia Genetics mitigates this by focusing on larger, sophisticated institutions where its value proposition of data sovereignty and capability-building is a key differentiator.
Execution on Path to Profitability: While management has a clear timeline to achieve breakeven, successful execution is paramount. The company is mitigating this risk by focusing on improving operational efficiency and expanding its high-margin software revenue streams.⁹
Patent Litigation: The ongoing lawsuit from Guardant Health presents a material risk. The company is actively defending its position, but an unfavorable outcome could impact its ability to operate in the liquid biopsy market.²⁹

Concluding Statement

Sophia Genetics has distinguished itself not merely as a technology provider, but as the architect of a global ecosystem. By championing a strategy of decentralization and collaboration, it has positioned itself as a critical enabler for the international healthcare community.

The company’s standout nature lies in its successful creation of a compounding competitive advantage through its network effect. This advantage is deeply integrated with its unique technology and business model. Future success will depend on its ability to continue expanding this network, deepening its multimodal data capabilities, and proving that a federated model is the superior path for personalized patient care.

Ultimately, Sophia Genetics is not just selling software; it is building the foundational infrastructure for a more equitable and intelligent era of global healthcare.

Works Cited

SOPHiA GENETICS. “Data to Decisions Faster: Pioneering the Future of Precision Medicine with the New Generation SOPHiA DDM™ Platform.”
SOPHiA GENETICS. “The Multimodal Imperative.”
SOPHiA GENETICS. “SOPHiA GENETICS Unveils New Generation of the SOPHiA DDM™ Platform at Morgan Stanley Healthcare Conference 2024.” September 4, 2024.
SOPHiA GENETICS. “Company Profile.”
SOPHiA GENETICS. “SOPHiA DDM™.”
SOPHiA GENETICS. “Two Million Patient Cases Analyzed, Marking New Milestone in Data-Driven Medicine at NVIDIA GTC.” March 18, 2025.
SOPHiA GENETICS. “SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results.” March 4, 2025.
SOPHiA GENETICS. “SOPHiA GENETICS Reports First Quarter 2025 Results.” May 6, 2025.
SOPHiA GENETICS. “2024 Swiss Annual Report.”
Wikipedia. “Sophia Genetics.”
SOPHiA GENETICS. “About Us.”
SOPHiA GENETICS. “Home Page.”
SOPHiA GENETICS. “Leadership Team.”
Axial. “The History of Sophia Genetics.” YouTube.
SOPHiA GENETICS. “Investor Relations.”
SOPHiA GENETICS. “Home Page.”
SOPHiA GENETICS. “SOPHiA DDM™.”
SOPHiA GENETICS. “Principles.”
SOPHiA GENETICS. “Industry Collaborations.”
SOPHiA GENETICS. “SOPHiA DDM™ for Genomics.”
SOPHiA GENETICS. “Industry Collaborations.”
SOPHiA GENETICS. “SOPHiA GENETICS Unveils New Generation of the SOPHiA DDM™ Platform at Morgan Stanley Healthcare Conference 2024.” September 4, 2024.
SOPHiA GENETICS. “Form 20-F for Fiscal Year 2024.”
SOPHiA GENETICS. “SOPHiA DDM™ for Genomics – Solid Tumors – HRD.”
SOPHiA GENETICS. “SOPHiA DDM™ for Genomics – Hereditary Cancers.”
SOPHiA GENETICS. “SOPHiA DDM™ for Genomics – Solid Tumors – CGP.”
PitchBook. “SOPHiA GENETICS Profile.” June 30, 2025.
Google Patents. “US20220310199A1 – Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next- generation sequencing data.”
JUVE Patent. “UPC sees next life sciences case as Guardant sues Sophia Genetics.” September 24, 2025.
SOPHiA GENETICS. “SOPHiA UNITY.”
PublicNow. “Annual Report for Fiscal Year Ending December 31, 2024 (Form 20-F).”
SOPHiA GENETICS. “Form 20-F for Fiscal Year 2023.”
SOPHiA GENETICS. “SOPHiA GENETICS Reports Second Quarter 2025 Results.” August 5, 2025.
SOPHiA GENETICS. “SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results.” March 4, 2025.
PitchBook. “SOPHiA GENETICS Financials.” June 30, 2025.
Guardant Health. “Home Page.”
Guardant Health. “Guardant360® CDx: Fastest FDA-Approved Liquid CGP Panel.”
Caris Life Sciences. “Home Page.”
Caris Life Sciences. “Home Page.”
NeoGenomics. “About NeoGenomics.”
NeoGenomics. “Home Page.”
Tempus. “Home Page.”
Tempus. “Home Page.”
PierianDx. “Home Page.”
PierianDx. “Clinical Genomics Workspace Software.”
SOPHiA GENETICS. “BioPharma – Diagnostics.”
SOPHiA GENETICS. “For BioPharma.”